Metraipolis › archive › dc_969f39bc0798

Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study — Europe PMC PMID:42382757

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42382757
DOI
10.3389/fimmu.2026.1809094
License (as archived)
solo-consultazione
Archived
2026-10-19T09:26:20.418Z
SHA-256 of the archived text
4bfaf3d5d0e13efb16d6e249d4a76171d3a2eb72b45f660c68ffee8550fd6237
Stable URL of this page
https://metraipolis.com/documento/dc_969f39bc0798

How to cite

Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study — Europe PMC PMID:42382757 — Europe PMC (en), https://europepmc.org/article/MED/42382757 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_969f39bc0798 (Metraipolis archive dc_969f39bc0798, sha256 4bfaf3d5d0e13efb16d6e249d4a76171d3a2eb72b45f660c68ffee8550fd6237)
BibTeX
@misc{dc969f39bc0798,
  title = {Adjuvant disitamab vedotin plus PD-1 blockade and gemcitabine/cisplatin in high-risk upper tract urothelial carcinoma: a two-stage real-world comparative study — Europe PMC PMID:42382757},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42382757},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_969f39bc0798; sha256 4bfaf3d5d0e13efb16d6e249d4a76171d3a2eb72b45f660c68ffee8550fd6237},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42382757. Agents can read the archived copy with the MCP tool read_document.